Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $49.41 million versus the consensus estimate of $20.92 million.

Financial Guidance for 2024

On a GAAP basis, we expect total operating expenses in the range of approximately $150 million to $170 million in 2024, which includes non-cash stock-based compensation expense, impairment expense, and depreciation and amortization.
We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, impairment expense of approximately $6 million, and depreciation and amortization of approximately $6 million, in the range of approximately $125 million to $145 million in 2024.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.